MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis Antonio Guasch, M.D., Carlos F. Zayas, Kamal F. Badr, M.D. Kidney International Volume 56, Issue 1, Pages 261-267 (July 1999) DOI: 10.1046/j.1523-1755.1999.00537.x Copyright © 1999 International Society of Nephrology Terms and Conditions
Figure 1 Structural formula of MK-591. Kidney International 1999 56, 261-267DOI: (10.1046/j.1523-1755.1999.00537.x) Copyright © 1999 International Society of Nephrology Terms and Conditions
Figure 2 The effects of treatment with MK-591 on albumin excretion rate (A) and IgG excretion rate (B) are shown. Mean values for protein excretion, pretreatment, and post-treatment are indicated separately by a solid circle with the vertical bar indicating theSEM.*P < 0.05. Kidney International 1999 56, 261-267DOI: (10.1046/j.1523-1755.1999.00537.x) Copyright © 1999 International Society of Nephrology Terms and Conditions
Figure 3 The fractional dextran clearances at baseline (▪) and after treatment with MK-591 (•) are shown. The dashed line (shown for comparison) indicates the fractional dextran clearance in 17 healthy individuals reported previously. *P < 0.05. Kidney International 1999 56, 261-267DOI: (10.1046/j.1523-1755.1999.00537.x) Copyright © 1999 International Society of Nephrology Terms and Conditions
Figure 4 Effects of treatment with MK-591 on glomerular membrane parameters and proteinuria: (A) main glomerular pores (ro), (B) shunt parameter (ωo), (C) fractional protein clearance via shunt (θ∞), (D) and the fractional clearances of albumin (○) and IgG (▵).*P < 0.05 vs. pretreatment. Kidney International 1999 56, 261-267DOI: (10.1046/j.1523-1755.1999.00537.x) Copyright © 1999 International Society of Nephrology Terms and Conditions